EVISA Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).

Supporters of EVISA includes:



A "second generation" platinum metallodrug effective in cancer chemotherapy that has been approved by the FDA for the treatment of ovarian cancers in 1989. Carboplatin is less toxic than the "first generation" antitumor drug, cisplatin.
IUPAC  name: cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II).

The term "carboplatin" was found in the following pages:


Imprint     Disclaimer

© 2003 - 2024 by European Virtual Institute for Speciation Analysis ( EVISA )